New research emphasizes benefits of Azilect in Parkinson’s
Azilect is indicated for the treatment of Parkinson's disease both as initial therapy alone and to be added to levodopa later in the disease. The study showed that
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.